Advancing Clinical Treatment – Hepatitis Liver Disease (ACT-LD), an aggregate corporation, is an internationally renowned organization that dedicates itself to preventive and diagnostic care of liver diseases.
The founding mission was to enhance advancement of medical knowledge exchange towards significant development in liver diseases through promoting public awareness in the field, improving care quality and treatment result for patients. In 2004, ACT-LD Taiwan was founded and kicked off in the United States.
In 2005, ACT-LD first reached Asia Pacific area, where Hepatitis B had been prevailing, and launched chapters in 14 Asia Pacific countries. In Taiwan, where efforts in prevention and treatment of liver diseases have been widely recognized, ACT-LD local chapter was established on November 29th, 2005.
ACT-LD Taiwan is under direction of a council of elite liver specialist doctors, with two major focuses: professional education and public awareness promotion. For professional education, ACT-LD Taiwan updates latest information and research development in liver diseases to doctors, so as to improve liver disease prevention, diagnosis and treatment in Taiwan. For raising public awareness, ACT-LD Taiwan starts from the basics by promoting the right concepts, hoping to mitigate the dire situation of prevailing liver diseases in Taiwan.
ACT-LD Taiwan is founded to promote right concepts of prevention, tracking and treatment of liver diseases, thereby improving liver treatment rate. By boosting awareness on liver disease treatment, ACT-LD Taiwan aims to enhance medical care quality and treatment result of Hepatitis B patients and other liver disease patients, easing the liver disease threat in Taiwan. Moreover, ACT-LD yearns to serve as a bridge that connects Taiwan to the world, facilitating most advanced medical knowledge exchange, providing the most accurate and comprehensive information as well as treatment approaches, eventually delivering a better life to all patients!
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close